[go: up one dir, main page]

NO992336D0 - Raf kinase inhibitors - Google Patents

Raf kinase inhibitors

Info

Publication number
NO992336D0
NO992336D0 NO992336A NO992336A NO992336D0 NO 992336 D0 NO992336 D0 NO 992336D0 NO 992336 A NO992336 A NO 992336A NO 992336 A NO992336 A NO 992336A NO 992336 D0 NO992336 D0 NO 992336D0
Authority
NO
Norway
Prior art keywords
kinase inhibitors
raf kinase
raf
inhibitors
kinase
Prior art date
Application number
NO992336A
Other languages
Norwegian (no)
Other versions
NO992336L (en
Inventor
Phillip John Hedge
Francis Thomas Boyle
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO992336L publication Critical patent/NO992336L/en
Publication of NO992336D0 publication Critical patent/NO992336D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO992336A 1996-11-16 1999-05-14 Raf kinase inhibitors NO992336D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623833.2A GB9623833D0 (en) 1996-11-16 1996-11-16 Chemical compound
PCT/GB1997/003102 WO1998022103A1 (en) 1996-11-16 1997-11-12 Raf kinase inhibitors

Publications (2)

Publication Number Publication Date
NO992336L NO992336L (en) 1999-05-14
NO992336D0 true NO992336D0 (en) 1999-05-14

Family

ID=10803023

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992336A NO992336D0 (en) 1996-11-16 1999-05-14 Raf kinase inhibitors

Country Status (8)

Country Link
EP (1) EP0941084A1 (en)
JP (1) JP2001504478A (en)
AU (1) AU4956297A (en)
CA (1) CA2267782A1 (en)
GB (1) GB9623833D0 (en)
NO (1) NO992336D0 (en)
WO (1) WO1998022103A1 (en)
ZA (1) ZA9710314B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
WO1999015164A1 (en) * 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
AU2198999A (en) * 1997-12-22 1999-07-12 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ID26328A (en) * 1997-12-22 2000-12-14 Bayer Ag ANALYSIS OF RAF KINASE USING ARTI AND HETEROARIL SUBSTITUTED HEREROSICLIC UREA
BR9910474A (en) * 1998-05-15 2001-01-02 Astrazeneca Ab Compound derived from amide, process for preparing it, pharmaceutical composition, and use of a compound derived from amide
PL197181B1 (en) * 1998-05-15 2008-03-31 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
NZ509318A (en) 1998-08-04 2002-10-25 Astrazeneca Ab Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines
BR9913947A (en) 1998-09-25 2001-06-12 Astrazeneca Ab Amide derivative, process for preparing the same or a pharmaceutically acceptable salt or cleavable ester in vivo thereof, use thereof, and pharmaceutical composition
DE69905264T2 (en) 1998-10-01 2003-12-11 Astrazeneca Ab, Soedertaelje CHINOLINE AND CHINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF DISEASES IN WHICH CYTOKINS ARE INVOLVED
WO2000021539A1 (en) * 1998-10-09 2000-04-20 Anadys Pharmaceuticals, Inc. Aryldiamine derivatives useful as antibacterial agents
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (en) 1999-01-13 2008-08-20 Байер Копэрейшн Derivatives of urea (variants), pharmaceutical composition (variants) and method for treatment of diseases associated with cancer cells growth (variants)
ES2377847T3 (en) 1999-01-13 2012-04-02 Bayer Healthcare Llc Diphenyl ureas substituted with omega-carboxy aryl as kinase inhibitors p38
JP4619545B2 (en) 1999-03-17 2011-01-26 アストラゼネカ アクチボラグ Amide derivatives
CA2361819A1 (en) * 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2471114C (en) 2001-12-21 2012-03-20 The Wellcome Trust Mutant b-raf polypeptide and a use thereof in the diagnosis of cancer
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
PT1580188E (en) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
ES2288694T3 (en) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation DIARIL UREAS FOR DISEASES MEDIATED BY THE RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES.
CA2531856C (en) * 2003-07-11 2013-07-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Benzimidazole carboxamides as raf kinase inhibitors
KR101139557B1 (en) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US20060025485A1 (en) * 2004-07-01 2006-02-02 Kyle Holen Hydroxybenazamide compounds for treatment of cancer
KR20070055575A (en) * 2004-09-01 2007-05-30 아스트라제네카 아베 Quinazolinone Derivatives and Uses thereof as J-RAF Inhibitors
WO2006067445A2 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
CA2594860A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1957461B1 (en) 2005-11-14 2016-11-02 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
SG183054A1 (en) 2007-04-20 2012-08-30 Deciphera Pharmaceuticals Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20110281893A1 (en) * 2010-05-11 2011-11-17 Krisani Biosciences (P) Ltd Compound, synthesis, composition and uses thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2013032979A1 (en) 2011-08-29 2013-03-07 Ticona Llc Melt polymerization of low melt viscosity liquid crystalline polymers
US9045685B2 (en) 2011-08-29 2015-06-02 Ticona Llc Cast molded parts formed from a liquid crystalline polymer
US9051514B2 (en) 2011-08-29 2015-06-09 Ticona Llc High flow liquid crystalline polymer composition
US8778221B2 (en) 2011-08-29 2014-07-15 Ticona Llc Aromatic amide compound
JP2014525499A (en) 2011-08-29 2014-09-29 ティコナ・エルエルシー Heat resistant liquid crystal polymer composition with low melting temperature
WO2013032975A1 (en) 2011-08-29 2013-03-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
WO2013032971A1 (en) 2011-08-29 2013-03-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
TW201319223A (en) 2011-08-29 2013-05-16 Ticona Llc High flow liquid crystalline polymer composition
HRP20181976T1 (en) 2012-03-29 2019-01-25 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
KR102708050B1 (en) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN114615982A (en) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 Ripoctinib for treating gastrointestinal stromal tumor
MX2022008103A (en) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Amorphous kinase inhibitor formulations and methods of use thereof.
CN118948772A (en) 2019-12-30 2024-11-15 德西费拉制药有限责任公司 Composition of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004170A1 (en) * 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics

Also Published As

Publication number Publication date
WO1998022103A1 (en) 1998-05-28
ZA9710314B (en) 1998-05-18
EP0941084A1 (en) 1999-09-15
NO992336L (en) 1999-05-14
JP2001504478A (en) 2001-04-03
CA2267782A1 (en) 1998-05-28
GB9623833D0 (en) 1997-01-08
AU4956297A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
NO992336D0 (en) Raf kinase inhibitors
NO20002121D0 (en) Benzothiazol-protein-tyrosine kinase inhibitors
DE69724809D1 (en) REFLUX INHIBITORS
FI963597A7 (en) Isoprenyltransferase inhibitors
NO972930D0 (en) Fibronectin-adhesion inhibitors
FI972160A0 (en) Matriisimetalloproteaasi inhibitors
DE69906554D1 (en) P38 INHIBITORS
DE69716615D1 (en) HETEROCYCLIC METALOPROTEAS INHIBITORS
DE69915704D1 (en) AMPIC DRAM
FI945706A7 (en) Protein kinase C inhibitors
ID22982A (en) SUBSTITUTED PIRAZOLS AS KINASE INHIBITORS p38
CY2007002I2 (en) O-CARBOXYARYLYPOsubstituted BINYLUREAS AS RAF KINASE INHIBITORS
NO974453L (en) Protein kinase C inhibitors
NO984316D0 (en) Skjμreverkt ° y
NO983462D0 (en) Isoleringsverkt ° y
DK0958287T3 (en) Sulfamidmetalloprotease inhibitors
DK1027332T3 (en) New lactametalloprotease inhibitors
PT956294E (en) TROMBIN INHIBITORS
NO990552D0 (en) Innrettingsverkt ° y
PT948483E (en) FARNESIL-TRANSFERASE INHIBITORS
ATE252547T1 (en) MATRIXMETALLOPROTEINASE INHIBITORS
EP1007548A4 (en) TSETSE-THROMBIN INHIBITOR
PT986382E (en) Raf kinase inhibitors
KR970059413U (en) level
CY2007006I2 (en) ALIPOPROTEIN-B INHIBITORS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application